From sick care to health care

The future of chronic respiratory & immune-mediated disease

By Caterina Brindicci Senior vice president & global head of research and development, respiratory & immunology, AstraZeneca

AZ | Article | Hero IMG

Today, most medicines used to treat challenging chronic respiratory and other immune-mediated diseases are focused on controlling symptoms, one disease at a time. For those with chronic obstructive pulmonary disorder (COPD) or asthma, who experience the breathlessness of an attack, or someone with lupus struggling to manage a myriad of symptoms during a flare-up, anything that provides relief feels life-changing. Yet we let the hundreds of millions of people1 living with these diseases go without optimal treatment — we’re leaving critical gaps in care and missing opportunities to improve outcomes.

Therefore, the question we need to ask is:

How can we do MORE to push the boundaries of science so that we are shifting from “sick” care, where we react by treating symptoms, to true “health” care – where our innovative approaches can intervene earlier to slow, reverse or even cure chronic respiratory and other immune-mediated diseases?

As a senior vice president & global head of research and development in respiratory & immunology at AstraZeneca, this question brings renewed focus and urgency to my work every day. And as a physician, I know how high the stakes are as we seek to drive this change.

The real – and growing – burden of chronic respiratory and other immune-mediated diseases

It is estimated that more than 2bn people have chronic diseases2-4 causing long-term suffering, disability and premature death.5 In the United States, 93% of adults over 65 live with one chronic condition, while nearly 79% have two or more.6 Globally, one in six people will be over the age of 60 in the next five years.7

93%

of adults over 65 in the United States live with a chronic condition.6

79%

of adults over 65 in the United States live with two or more chronic conditions.6

1 in 6

people will be over age 60 in the next five years globally.7

Driven by a dysregulated immune response across conditions, from asthma8 and COPD9 to lupus and other autoimmune diseases,10 people can experience repeated life-threatening events, resulting in cycling through multiple therapies and experiencing disease progression that leaves them with irreversible organ damage.11-14 This translates to a significant physical and mental burden for individuals and economic burden for health systems.11,14-17

US$4.3 trillion

Without effective intervention, the global economic burden of COPD alone is estimated to be US$4.3 trillion by 2050.18

With an ageing population, rising comorbidities and strained healthcare systems, this challenge will only get worse. Without effective intervention, the global economic burden of COPD alone – just one of the many respiratory diseases that contribute to economic health burden – is estimated to be US$4.3trn by 2050.18

Urgency needs to go beyond the symptom and into the science

A clear scientific mission exists to deliver the next wave of innovation to patients in need. It starts with accelerating our innovation to identify and target the biological drivers that lower disease activity and address the underlying immune response.

With innovations such as novel oral and inhaled therapies, we believe we can improve outcomes beyond current standards of care and expand our reach to more patients. Targeting overlapping pathways with a new generation of multi-mechanism biologics, cell therapy and T-cell engagers could help us go further to rebalance and even “reset” immune cell function, addressing the cause, not the effect. We are investing in, and harnessing, a diverse range of therapeutic approaches and modalities to ensure we can design and develop the best treatment solutions to address the novel biology we uncover.

Expanding scientific capabilities like these, guided by insights from large-scale genomics and clinical data, has the potential to finally provide relief, transformative efficacy – and even, one day, a cure.

AZ | Article | Body IMG 1

We recognise we cannot do it alone. It will take the full community – clinicians, patients, advocates and policymakers – working in partnership to break sometimes decades-long inertia in care and to take on challenges as significant as the health conditions we are focused on, including COPD, asthma, lupus and immune-mediated diseases where unmet need remains.

Evolving from sick care to health care

Earlier intervention is foundational, and this means not only improving diagnosis and optimising treatments today, but creating next-generation therapies that can expand access and reach patients across the disease journey. For example, by intervening five years earlier, asthma treatment with biologics could prevent nearly 2,000 deaths from severe asthma in the UK alone.19 Without early intervention, the number of COPD patients could balloon to 600m cases worldwide by 2050.20

~2000 deaths

By intervening five years earlier, asthma treatment with biologics could prevent nearly 2,000 deaths from severe asthma in the U.K. alone.19

At the same time, progress in diagnostics, novel endpoints and genomic data is redefining how and when we act — enabling earlier detection, treatment and care strategies that mirror the complexity of the human body.

To achieve bold scientific impact, it is critical to generate real-world successes for how emerging science and care come together to deliver better health.

New models for care are transforming lives and saving health systems millions. An integrated disease management model in Canada (Best Care COPD) moved patients to guideline-directed treatment and delivered a 47-72% reduction in COPD-related hospital admissions over three years.21 It also saved the health system millions of dollars.22

Advanced therapies must reach patients sooner for real change. Transformational health outcomes will only be achieved when patients have access to the breakthroughs we develop and discover in the lab.

AZ | Article | Body IMG 2

Now is the time to start changing the future of chronic respiratory and immune-mediated disease

At AstraZeneca, we’re taking bold steps to make this future happen now. My team is driven by a legacy of innovation in immune science and a relentless resolve to spark a revolution in immune-mediated diseases — in and beyond the lung. With millions of lives at stake, we are working with the urgency this challenge demands to deliver a transformational shift from “sick” care to “health” care.

Let’s work together towards a world where every patient receives the care they deserve. Our pursuit won’t waver until this vision is realised for all.

About the author:

AZ | Article | Author IMG
Caterina Brindicci

Senior vice president & global head of research and development, respiratory & immunology, AstraZeneca

Veeva ID: Z4-76925 | Date of Preparation: September 2025

References

  1. AstraZeneca. Data on File 2025. Chronic Respiratory and Immune Mediated Disease Figure and Burden. REF-249709.

  2. British Heart Foundation. Global Cardiovascular Disease Fact Sheet. Available at: https://www.bhf.org.uk/-/media/files/for-professionals/research/heart-statistics/bhf-cvd-statistics-global-factsheet.pdf. [Last accessed: September 2025].

  3. GBD 2019 Chronic Respiratory Diseases Collaborators. Global burden of chronic respiratory diseases and risk factors, 1990-2019: an update from the Global Burden of Disease Study 2019. eClinicalMedicine. 2023; 59:101936.

  4. Chew NWS, et al. The global burden of metabolic disease: Data from 2000 to 2019. Cell Metab. 2023; 35(3):414-428.e3.

  5. CDC. Chronic Disease. Available at: https://www.cdc.gov/chronic-disease/about/index.html. [Last accessed: September 2025].

  6. National Council on Aging. The Top 10 Most Common Chronic Conditions in Older Adults. Available at: https://www.ncoa.org/article/the-top-10-most-common-chronic-conditions-in-older-adults. [Last accessed: September 2025].

  7. World Health Organization. Ageing and health. Available at: https://www.who.int/news-room/fact-sheets/detail/ageing-and-health. [Last accessed: September 2025].

  8. Chang YS, et al. Immune network dysregulation precedes clinical diagnosis of asthma. Sci Rep. 2020; 10:12784.

  9. Pang X, Liu X. Immune Dysregulation in Chronic Obstructive Pulmonary Disease. Immunol Invest. 2024; 53(4):652-694.

  10. Ohmes J, et al. Dysregulation and chronicity of pathogenic T cell responses in the pre-diseased stage of lupus. Front Immunol. 2022; 13:1007078.

  11. Igboekwe E, et al. Real-World Disease Burden and Healthcare Resource Utilization Among Patients with COPD and Asthma Using Triple Therapy (FF/UMEC/VI) in the United States. Int J Chron Obstruct Pulmon Dis. 2024; 19:281-296.

  12. Labaki WW, Han MK. Chronic respiratory diseases: a global view. Lancet Respir Med. 2020; 8(6):531-533.

  13. Barber MRW, et al. Global epidemiology of systemic lupus erythematosus. Nat Rev Rheumatol. 2021; 17(9):515-532.

  14. Hammond ER, et al. Frequency, severity and costs of flares increase with disease severity in newly diagnosed systemic lupus erythematosus: a real-world cohort study, United States 2004-2015. Lupus Sci Med. 2021; 8(1):e000504.

  15. Olesińska M, Saletra A. Quality of life in systemic lupus erythematosus and its measurement. Reumatologia. 2018; 56(1):45-54.

  16. Stanescu S, et al. A systematic review of psychological, physical health factors, and quality of life in adult asthma. NPJ Prim Care Respir Med. 2019; 29(1):37.

  17. Wang J, et al. The complexity of mental health care for people with COPD: a qualitative study of clinicians’ perspectives. NPJ Prim Care Respir Med. 2021; 31(1):40.

  18. Chen S, et al. The global economic burden of chronic obstructive pulmonary disease for 204 countries and territories in 2020-50: a health-augmented macroeconomic modelling study. Lancet Glob Health. 2023; 11(8):e1183-e1193.

  19. AstraZeneca. Data on File 2025. Modelling patient and health system benefits of earlier biologic treatment for patients with severe asthma. REF-280329.

  20. Boers E, et al. Global Burden of Chronic Obstructive Pulmonary Disease Through 2050. JAMA Netw Open. 2023; 6(12):e2346598.

  21. Licskai C, et al. Quantifying sustained health system benefits of primary care-based integrated disease management for COPD: a 6-year interrupted time series study. Thorax. 2024; 79(8):725-734.

  22. Adams E, et al. Estimating the Health and Economic Impact of Improved Management in Prevalent Chronic Obstructive Pulmonary Disease Populations in England, Germany, Canada, and Japan: A Modelling Study. Int J Chron Obstruct Pulmon Dis. 2023; 18:2127-2146.